1.

Record Nr.

UNINA990000120040403321

Autore

Fréchette, Van Derck <1916- >

Titolo

Failure analysis of brittle materials / V. D. Frechette

Pubbl/distr/stampa

Westerville : The American ceramic society, copyr. 1990

ISBN

0 944904 30 0

Descrizione fisica

XI, 136 p. : ill. ; 24 cm

Collana

Advances in ceramics ; 28

Disciplina

620.112 6

Locazione

DINMP

FINBC

Collocazione

14 C.010.097

13 B 42 26

Lingua di pubblicazione

Italiano

Formato

Materiale a stampa

Livello bibliografico

Monografia



2.

Record Nr.

UNISA996395993803316

Autore

Fabyan Robert <d. 1513.>

Titolo

[Capitulum. CC.xix.] [[electronic resource]]

Pubbl/distr/stampa

[London, : R. Pynson, 1516]

Descrizione fisica

[2+] leaves

Soggetti

Great Britain History To 1485 Early works to 1800

Great Britain History Tudors, 1485-1603 Early works to 1800

France History Early works to 1800

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Caption title.

Author, uniform title, and imprint suggested by STC.

Fragment of: Newe cronycles of Englande and of Fraunce.

First lines of text: Willyam Duke of Normandye surnamed Co~querour ...

Imperfect: cropped with some loss of text.

Reproduction of original in the British Library.

Sommario/riassunto

eebo-0018



3.

Record Nr.

UNINA9910136806603321

Autore

Marc H. V. Van Regenmortel

Titolo

Paradigm changes are required in HIV vaccine research

Pubbl/distr/stampa

Frontiers Media SA, 2015

Descrizione fisica

1 online resource (74 p.)

Collana

Frontiers Research Topics

Soggetti

Medicine

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Sommario/riassunto

In his 1962 book "The Structure of Scientific Revolutions", Thomas Kuhn famously argued that researchers in every field of scientific enquiry always operate under a set of presuppositions known as paradigms that are rarely explicitly stated. In the field of HIV vaccine research, several prevailing paradigms led scientists for many years to pursue unfruitful lines of investigations that impeded significant progress. The uncritical acceptance of reigning paradigms makes scientists reluctant to abandon their mistaken assumptions even when they obtain results that are not consistent with the paradigms. The following five paradigms which disregard the degeneracy of the immune system were particularly harmful. 1) There is a primary and intrinsic epitope specific for each B cell receptor and for the corresponding monoclonal antibody. In reality, there is no single, intrinsic or "real" epitope for any antibody but only a diverse group of potential ligands. 2) Reactions with monoclonal antibodies are more specific than the combined reactivity of polyclonal antibodies. In reality, a polyclonal antiserum has greater specificity for a multiepitopic protein because different antibodies in the antiserum recognize separate epitopes on the same protein, giving rise to an additive specificity effect. By focusing vaccine design on single epitope-Mab pairs, the beneficial neutralizing synergy that occurs with polyclonal antibody responses is overlooked. 3) The HIV epitope identified by solving the crystallographic structure of a broadly neutralizing Mab -



HIV Env complex should be able, when used as immunogen, to elicit antibodies endowed with the same neutralizing capacity as the Mab. Since every anti HIV bnMab is polyspecific, the single epitope identified in the complex is not necessarily the one that elicited the bnMab. Since hypermutated Mabs used in crystallographic studies differ from their germline-like receptor version present before somatic hypermutation, the identified epitope will not be an effective vaccine immunogen. 4) Effective vaccine immunogenicity can be predicted from the antigenic binding capacity of viral epitopes. Most fragments of a viral antigen can induce antibodies that react with the immunogen, but this is irrelevant for vaccination since these antibodies rarely recognize the cognate, intact antigen and even more rarely neutralize the infectivity of the viral pathogen that harbors the antigen. 5) The rational design of vaccine immunogens using reverse vaccinology is superior to the trial-and-error screening of vaccine candidates able to induce protective immunity. One epitope can be designed to increase its structural complementarity to one particular bnMab, but such antigen design is only masquerading as immunogen design because it is assumed that antigenic reactivity necessarily entails the immunogenic capacity to elicit neutralizing antibodies. When HIV Env epitopes, engineered to react with a bnMab are used to select from human donors rare memory B cells secreting bnAbs, this represents antigen design and not immunogen design. The aim of this Research Topic is to replace previous misleading paradigms by novel ones that better fit our current understanding of immunological specificity and will help HIV vaccine development.